Virtual Library
Start Your Search
C. Griffin
Author of
-
+
P3.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 235)
- Event: WCLC 2015
- Type: Poster
- Track: Biology, Pathology, and Molecular Testing
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.04-022 - The Johns Hopkins University TCGA Experience (ID 2874)
09:30 - 09:30 | Author(s): C. Griffin
- Abstract
Background:
The Cancer Genome Atlas (TCGA) is a genomic mapping effort that characterizes and analyzes the major types of cancer. Specimens have to meet strict tissue criteria to become eligible for shipment to TCGA and used for genomic analysis. Johns Hopkins University (JHU) is a part of the TCGA network and we have sent numerous biospecimens for analysis. Our experience is catalogued over 3 different shipments and may be unique only to JHU. This paper will analyze if the JHU samples that have qualified for TCGA are representative of the overall selected lung cancer samples.
Methods:
We analyzed the JHU cohort using TCGA’s shipment qualification reports in addition to our biospecimen data pre-selected for TCGA. Specimens with at least 60% tumor qualified for TCGA and those that disqualified were because of lack of RNA. Specimens that were not eligible for shipment had less than 60% tumor.
Results:
There is a trend in older specimens being disqualified throughout the TCGA shipments. In contrast, those specimens that were cut but deemed ineligible to be sent to TCGA tended to be older, male, adenocarcinoma (p=0.003), and earlier stage (p=0.010) than those that were actually shipped. The majority of the specimens that were shipped were sent during shipment 1 (p<0.001) and the proportion of specimens sent were older (long surgery to cut duration) than younger comparing specimens with durations of 0 years, 1-10 years, and 11-21 years (p<0.001). Figure 1 Figure 2
Conclusion:
Our data suggests that older specimens were the most likely to be disqualified when shipped to the TCGA as well as those that were not sent but were cut for shipment. Future research should focus on developing more advanced technology that will allow the inclusion of a wide range of specimens that do not exclude a large part of the lung cancer population.
